Orbimed Advisors LLC cut its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) by 18.2% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,425,200 shares of the biotechnology company’s stock after selling 316,600 shares during the period. Orbimed Advisors LLC’s holdings in BioCryst Pharmaceuticals were worth $13,568,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock valued at $173,732,000 after buying an additional 482,494 shares during the period. RA Capital Management L.P. bought a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. raised its stake in BioCryst Pharmaceuticals by 159.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock worth $92,363,000 after buying an additional 7,477,000 shares during the period. State Street Corp raised its stake in BioCryst Pharmaceuticals by 12.9% during the 4th quarter. State Street Corp now owns 11,073,211 shares of the biotechnology company’s stock worth $86,371,000 after buying an additional 1,265,773 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after acquiring an additional 7,310,745 shares in the last quarter. 85.88% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on BCRX shares. Weiss Ratings reissued a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Wall Street Zen cut BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Tuesday, June 30th. Wedbush lowered their target price on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.80.
BioCryst Pharmaceuticals Price Performance
BCRX opened at $9.34 on Monday. The company has a market capitalization of $2.37 billion, a price-to-earnings ratio of -5.25 and a beta of 0.55. The business’s 50-day moving average price is $9.22 and its two-hundred day moving average price is $8.58. BioCryst Pharmaceuticals, Inc. has a 1 year low of $6.00 and a 1 year high of $11.22.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million for the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The firm’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.20 earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current fiscal year.
BioCryst Pharmaceuticals Profile
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
Featured Articles
- Five stocks we like better than BioCryst Pharmaceuticals
- RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade?
- These 4 Earnings Reports Expose the Market’s Growing Economic Divide
- Broadcom May Be the Biggest Winner From Alphabet’s Earnings
- Volatility Is Back and These 3 Market Tollbooths Are Best Positioned to Profit
Want to see what other hedge funds are holding BCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report).
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
